Log in

NASDAQ:ALNAAllena Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$1.24
MA: $1.56
$2.16
52-Week Range N/A
Volume843,051 shs
Average Volume2.55 million shs
Market Capitalization$36.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Read More
Allena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share

Profitability

Net Income$-47,340,000.00

Miscellaneous

Employees34
Market Cap$36.87 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Allena Pharmaceuticals
.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Allena Pharmaceuticals
.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals Inc (NASDAQ:ALNA) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01.
View Allena Pharmaceuticals' earnings history
.

What price target have analysts set for ALNA?

7 equities research analysts have issued twelve-month target prices for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $26.00. On average, they expect Allena Pharmaceuticals' stock price to reach $11.00 in the next twelve months.
View analysts' price targets for Allena Pharmaceuticals
.

Has Allena Pharmaceuticals been receiving favorable news coverage?

Media headlines about ALNA stock have been trending very negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Allena Pharmaceuticals
.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 739,100 shares, an increase of 42.7% from the June 30th total of 518,100 shares. Based on an average trading volume of 1,150,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 3.4% of the company's stock are short sold.
View Allena Pharmaceuticals' Short Interest
.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Exelixis (EXEL), Matinas BioPharma (MTNB), Opko Health (OPK), Amarin (AMRN) and Pieris Pharmaceuticals (PIRS).

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)
  • Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)
  • Mr. Hugh Wight, Sr. VP of Technical Operations

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.20%).
View institutional ownership trends for Allena Pharmaceuticals
.

Which institutional investors are buying Allena Pharmaceuticals stock?

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Allena Pharmaceuticals
.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $0.00. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.